Cargando…

Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome

Although several risk factors exist for acute coronary syndrome (ACS) no biomarkers for survival or risk of re-infarction have been validated. Previously, reduced serum concentrations of anti-ß(1)AR Ab have been implicated in poorer ACS outcomes. This study further evaluates the prognostic implicati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ernst, Diana, Westerbergh, Johan, Sogkas, Georgios, Jablonka, Alexandra, Ahrenstorf, Gerrit, Schmidt, Reinhold Ernst, Heidecke, Harald, Wallentin, Lars, Riemekasten, Gabriela, Witte, Torsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787077/
https://www.ncbi.nlm.nih.gov/pubmed/31601947
http://dx.doi.org/10.1038/s41598-019-51125-9
Descripción
Sumario:Although several risk factors exist for acute coronary syndrome (ACS) no biomarkers for survival or risk of re-infarction have been validated. Previously, reduced serum concentrations of anti-ß(1)AR Ab have been implicated in poorer ACS outcomes. This study further evaluates the prognostic implications of anti-ß(1)AR-Ab levels at the time of ACS onset. Serum anti-ß(1)AR Ab concentrations were measured in randomly selected patients from within the PLATO cohort. Stratification was performed according to ACS event: ST-elevation myocardial infarct (STEMI) vs. non-ST elevation myocardial infarct (NSTEMI). Antibody concentrations at ACS presentation were compared to 12-month all-cause and cardiovascular mortality, as well as 12-month re-infarction. Sub-analysis, stratifying for age and the correlation between antibody concentration and conventional cardiac risk-factors was subsequently performed. Serum anti-ß(1)AR Ab concentrations were measured in 400/799 (50%) STEMI patients and 399 NSTEMI patients. Increasing anti-ß(1)AR Ab concentrations were associated with STEMI (p = 0.001). Across all ACS patients, no associations between anti-ß(1)AR Ab concentration and either all-cause cardiovascular death or myocardial re-infarction (p = 0.14) were evident. However among STEMI patients ≤60 years with anti-ß(1)AR Ab concentration <median higher rates of re-infarction were observed, compared to those with anti-ß(1)AR Ab concentrations > median (14/198 (7.1%) vs. 2/190 (1.1%)); p = 0.01). Similarly, the same sub-group demonstrated greater risk of cardiovascular death in year 1, including re-infarction and stroke (22/198 (11.1%) vs. 10/190 (5.3%); p = 0.017). ACS Patients ≤60 years, exhibiting lower concentrations of ß(1)AR Ab carry a greater risk for early re-infarction and cardiovascular death. Large, prospective studies quantitatively assessing the prognostic relevance of Anti-ß(1)AR Ab levels should be considered.